Featuring detailed profiles of the Chinese tech companies making waves, the tech sectors that matter most in China's grab for super power status, and predictions for China's tech dominance in just 10 years. The rise of China's tech companies and intense competition from the sector is just beginning. This will present an ongoing management and strategy challenge for companies for many years to come. Tech Titans of China is the go-to-guide for companies (and those interested in competition from China) seeking to understand China's grand tech ambitions, who the players are and what their strategy is. Fannin, a leading expert on the Chinese tech sector, is an internationally-recognized journalist, author and speaker. Through her company, Silicon Dragon, Fannin hosts 12 live events annually for business leaders, venture capitalists, start-up founders, and others impacted by or interested in the Chinese tech industry.

"Free as in Freedom" interweaves biographical snapshots of GNU project founder Richard Stallman with the political, social and economic history of the free software movement. It examines Stallman's unique personality and how that personality has been at turns a driving force and a drawback in terms of the movement's overall success.

"Free as in Freedom" examines one man's 20-year attempt to codify and communicate the ethics of 1970s era "hacking" culture in such a way that later generations might easily share and build upon the knowledge of their computing forebears. The book documents Stallman's personal evolution from teenage misfit to prescient adult hacker to political leader and examines how that evolution has shaped the free software movement. Like Alan Greenspan in the financial sector, Richard Stallman has assumed the role of tribal elder within the hacking community, a community that bills itself as anarchic and averse to central leadership or authority. How did this paradox come about? "Free as in Freedom" provides an answer. It also looks at how the latest twists and turns in the software marketplace have diminished Stallman's leadership role in some areas while augmenting it in others.

Finally, "Free as in Freedom" examines both Stallman and the free software movement from historical viewpoint. Will future generations see Stallman as a genius or crackpot? The answer to that question depends partly on which side of the free software debate the reader currently stands and partly upon the reader's own outlook for the future. 100 years from now, when terms such as "computer," "operating system" and perhaps even "software" itself seem hopelessly quaint, will Richard Stallman's particular vision of freedom still resonate, or will it have taken its place alongside other utopian concepts on the 'ash-heap of history?'

Scientists in the biotechnology sector have developed a vast array of products and procedures, including drugs, diagnostics, agricultural products and veterinary procedures. This is made possible through various intra- and inter-organizational collaborations between the academic and private sectors, and through the establishment of networks for learning. In Networks for Learning and Knowledge Creation in Biotechnology, Amalya Lumerman Oliver shows how, in many respects, the organizational structure of the industry parallels one of its most important innovations - recombinant DNA (rDNA). She shows how the concept of recombination can be used to explain a number of organizational elements, including new biotechnology firms, the form of university-based spin-offs, scientific entrepreneurship, and trust and contracts in learning collaborations and networks. The result is a stimulating account of how multiple theoretical perspectives can be used to understand the structure of the biotechnology industry.

"Sony vs. Samsung" is business history at its best! It explores the divergent fortunes of these two electronics giants in the last decade and identifies the true reasons behind Sony's decline and Samsung's rise. Contrary to popular belief, Chang shows that success (or failure) does not simply arise from different strategies. Rather, it emerges from major decisions that are deeply rooted in the companies' organizational processes and their executives' political behavior. This book is a must-read for any senior executive. --Constantinos Markides
"Robert P. Bauman Professor of Strategic Leadership and Chairman,
Strategy Department, London Business School"

Sea-Jin Chang has produced that rarity in a business book--one that is as valuable to practicing managers as it is insightful to academic researchers. In this fascinating comparison of two modern global giants, he applies his high resolution research microscope to their changing fortunes by dissecting their contrasting strategies, and providing interesting insights into their divergent organizational processes and management practices. This is a very valuable contribution to the international business literature. It will end up in as many corporate boardrooms as faculty seminars.--Christopher A. Bartlett
"Thomas D. Casserly Professor Emeritus, Harvard Business School"

Sea-Jin Chang has written a fascinating comparison of Sony and Samsung that will be valuable to anyone interested in strategy, organizations or international business. The interwoven and very detailed case studies of two very different companies in overlapping industries illuminate problems such as adaptation to technological change (analog to digital), organizational flexibility and globalization. His attempt to analyze both strategic development and implementation is successful and very useful. Both academics and practitioners will learn a lot from this book.--Stephen J. Kobrin, "William Wurster Professor of Multinational Management, The Wharton School, University of Pennsylvania"

Refreshingly original and entertaining, this book analyzes major strategic decisions of Samsung and Sony and highlights organizational processes and top management leadership that have shaped their performances. This is a must-read for all executives who want to understand the strengths and weaknesses of Asian competitors. It also provides penetrating insights to other Asian companies with global ambitions.-- Myoung Woo Lee, "President and CEO
iriver"

High technology--which accounts for a rapidly growing section of the global workforce--presents a different set of management problems than have usually been encountered by traditional industry. In this book, Von Glinow, Mohrman, and their expert contributors discuss the reasons for this difference and define new organizational forms for global high technology management. Propounding a revolutionary approach to high technology management issues, they explore management teams, high velocity environments, and high technology marketing, as well as human resource considerations, including team interdependence, compensation, and culture clash.

A New York Times bestseller.

Winner of the Financial Times/McKinsey Business Book of the Year Award.

'Chilling . . . Reads like a West Coast version of All the President’s Men.' New York Times Book Review

The full inside story of the breathtaking rise and shocking collapse of Theranos, the multibillion-dollar biotech startup, by the prize-winning journalist who first broke the story and pursued it to the end, despite pressure from its charismatic CEO and threats by her lawyers.

In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood testing significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work.

In Bad Blood, John Carreyrou tells the riveting story of the biggest corporate fraud since Enron, a tale of ambition and hubris set amid the bold promises of Silicon Valley.

Now to be adapted into a film, with Jennifer Lawrence to star.

The objective of a synchronized production system is to harmonize all the elements of the manufacturing process based on the Just-in-Time strategy. This strategy is designed to improve return on investment in business by reducing in-process inventory and its associated costs. The process is driven by a series of signals, or Kanban, that tell production processes to make the next part. The Synchronized Production System sets out the fundamentals of the process clearly and concisely and shows the remarkable results that can be achieved: Money previously tied up in stock is released Quicker response times to customer orders, leading to increased customer satisfaction Custom manufacture to order - improving equity return by reducing risk Dramatically improved product quality This ground-breaking book also explains how to improve performance through changes to management processes making it an invaluable reference for managers in all types and size of business.

What do CERN, smartphones, the iridium satellite network, the most popular app stores in the world, the biggest online game in the world, Moscow drivers, Seniors golfer Tony Johnstone, sufferers of rheumatoid arthritis and anyone who has their DNA sequenced have in common? They all rely on innovations that have come out of the technology cluster known as the Cambridge Phenomenon. This book, a follow-up to The Cambridge Phenomenon: 50 Years of Innovation and Enterprise, showcases what the Cambridge technology cluster has done for the world. The Cambridge Phenomenon: Global Impact reveals just how many of us, all around the globe, rely on Cambridge technology every day. This book tells the important, hidden story of how academic excellence and entrepreneurial endeavour have improved people's lives the world over. It is crucial reading for anybody interested in the ways successful businesses work, and the fundamental role of our great educational institutions in fostering that success.

The Silicon phenomenon was, is, and will be an extremely important phenomenon in the accelerated technological, scientific, and economic development of countries and regions. Silicon Valley North (SVN) is the high tech capital of Canada, the nation??'s most developed and dynamic technology sector, which includes multiple clusters in telecommunications, software, photonics, and life sciences. It gave birth to many well-known companies such as Corel, JDS Uniphase, Mitel, Newbridge Networks, Nortel Networks, Digital Equipment of Canada, just to mention a few. A lot of literature describes Silicon Valley and Silicon Alley in the US, Silicon Islands in Asia, and so on. Despite the quite evident importance of Silicon Valley North for the regional, national, and international technological development (especially when Nortel Networks and JDS Uniphase became global leaders in their fields and expanded in explosive fashion), this phenomenon is far from being well understood. Because of this, a book on the Canadian Silicon Valley is an exceptionally timely endeavor.
Silicon Valley North: A High-Tech Cluster of Innovation and Entrepreneurship is devoted to the multidimensional and multifaceted nature of SVN, its history, current state and future developments. The book offers a broad and deeply thematic analysis of one particular innovative cluster???Silicon Valley North. The reader will obtain expert insight into what SVN is all about by acquiring a comprehensive and "panoramic picture" of SVN within a single book. The reader will develop an accurate sense of what spurs high tech start-up companies in SVN toward their exceptional performances, and how to apply these insights to his or herunique regional context.

High-tech businesses form a crucial part of entrepreneurial activity in some ways representing very typical examples of entrepreneurship, yet in some ways representing quite different challenges. The uncertainty in innovation and advanced technology makes it difficult to use conventional economic planning models, and also means that the management skills used in this area must be more responsive to issues of risk, uncertainty and evaluation than in conventional business opportunities.
While entrepreneurial courses do reflect the importance of high-tech businesses, they often lack the resources needed to teach this in a way that goes beyond standard how to start up a business courses whilst not focusing solely on theoretical models. This book specifically focuses on the mix of theory and practice needed to accurately inform students. Key topics covered include:
* uncertainty and innovation
* entrepreneurial finance
* marketing technological innovations
* high-tech incubation management.
Including case studies to give practical insights into genuine business examples, this comprehensive book has a distinctly real-world focus throughout. Edited by a multi-national team, it draws together leading writers and researchers from across Europe, and is therefore a must-read for all those involved in advanced entrepreneurship with specific interests in high-tech start-ups.

Agricultural (or "green") biotechnology is a source of growing tensions in the global trading system, particularly between the United States and the European Union. Genetically modified food faces an uncertain future. The technology behind it might revolutionize food production around the world. Or it might follow the example of nuclear energy, which declined from a symbol of socioeconomic progress to become one of the most unpopular and uneconomical innovations in history.

This book provides novel and thought-provoking insights into the fundamental policy issues involved in agricultural biotechnology. Thomas Bernauer explains global regulatory polarization and trade conflict in this area. He then evaluates cooperative and unilateral policy tools for coping with trade tensions. Arguing that the tools used thus far have been and will continue to be ineffective, he concludes that the risk of a full-blown trade conflict is high and may lead to reduced investment and the decline of the technology. Bernauer concludes with suggestions for policy reforms to halt this trajectory--recommendations that strike a sensible balance between public-safety concerns and private economic freedom--so that food biotechnology is given a fair chance to prove its environmental, health, humanitarian, and economic benefits.

This book will equip companies, farmers, regulators, NGOs, academics, students, and the interested public--including both advocates and critics of green biotechnology--with a deeper understanding of the political, economic, and societal factors shaping the future of one of the most revolutionary technologies of our times.

Best Practices in Biotechnology Education describes a wide variety of programs from high school through Ph.D. programs. Some are in their first years, whereas others are quite mature and have diversified to offer myriad degree and certificate options. There is also strong international representation, with programs from Australia, Canada, New Zealand, South Africa, and the United States. Best Practices in Biotechnology Education is directed at faculty seeking to start or expand biotechnology education programs; policy-makers and economic developers seeking to help meet workforce needs; and, students, scientists, and business professionals looking to enter the industry or upgrade their existing skills.

Translational Biotechnology: A Journey from Laboratory to Clinics presents an integrative and multidisciplinary approach to biotechnology to help readers bridge the gaps between fundamental and functional research. The book provides state-of-the-art and integrative views of translational biotechnology by covering topics from basic concepts to novel methodologies. Topics discussed include biotechnology-based therapeutics, pathway and target discovery, biological therapeutic modalities, translational bioinformatics, and system and synthetic biology. Additional sections cover drug discovery, precision medicine and the socioeconomic impact of translational biotechnology. This book is valuable for bioinformaticians, biotechnologists, and members of the biomedical field who are interested in learning more about this promising field.

Why is it that in the '90s, business in California's Silicon Valley flourished, while along Route 128 in Massachusetts it declined? The answer, Annalee Saxenian suggests, has to do with the fact that despite similar histories and technologies, Silicon Valley developed a decentralized but cooperative industrial system while Route 128 came to be dominated by independent, self-sufficient corporations. The result of more than one hundred interviews, this compelling analysis highlights the importance of local sources of competitive advantage in a volatile world economy.

The book examines the evolution of one of the most important technologies that has emerged in the last fifty years: biotechnology - the use of living organisms, or parts thereof to create useful products and services. The most important application of biotechnology has been in medicine, in the development of new drugs. The central purpose of the book is to explain how firms based in the US took the lead in commercialising the technology, and why it has been so difficult for firms in other countries to match what the leading American companies have achieved. The book looks at the institutions and policies which have underpinned US success in biotechnology. This is the US innovation "ecosystem," and it is made up of several interlocking elements which constitute a powerful competitive advantage for US biotechnology firms. These include, a higher education system which has close links with industry, massive support from the Federal government for biomedical research, and a financial system which is well equipped to support young entrepreneurial firms in a science-based industry. In the light of US experience the book examines in detail the performance of UK biotechnology firms over the past forty years, starting with the creation of the UK's first dedicated biotech firm, Celltech, in 1980. The book shows how the UK made a promising start in the 1980s and 1990s but failed to build on it. Several leading firms failed, and after an initial burst of enthusiasm investors lost confidence in the British biotech sector. It is only the last few years that the sector has staged a revival, attracting fresh investment from the US as well from the UK. The story told in this book, based on extensive interviews with industry participants, investors, and policy makers in the UK, Continental Europe, and the US, sheds new light on one of the central issues facing governments in the advanced industrial countries - how to create and sustain new science-based industries.

Agricultural (or "green") biotechnology is a source of growing tensions in the global trading system, particularly between the United States and the European Union. Genetically modified food faces an uncertain future. The technology behind it might revolutionize food production around the world. Or it might follow the example of nuclear energy, which declined from a symbol of socioeconomic progress to become one of the most unpopular and uneconomical innovations in history. This book provides novel and thought-provoking insights into the fundamental policy issues involved in agricultural biotechnology. Thomas Bernauer explains global regulatory polarization and trade conflict in this area. He then evaluates cooperative and unilateral policy tools for coping with trade tensions. Arguing that the tools used thus far have been and will continue to be ineffective, he concludes that the risk of a full-blown trade conflict is high and may lead to reduced investment and the decline of the technology. Bernauer concludes with suggestions for policy reforms to halt this trajectory--recommendations that strike a sensible balance between public-safety concerns and private economic freedom--so that food biotechnology is given a fair chance to prove its environmental, health, humanitarian, and economic benefits. This book will equip companies, farmers, regulators, NGOs, academics, students, and the interested public--including both advocates and critics of green biotechnology--with a deeper understanding of the political, economic, and societal factors shaping the future of one of the most revolutionary technologies of our times.

The sixth installment of the "Fisher Investments On" series is a comprehensive guide to understanding and analyzing investment opportunities within the Technology sector. "Fisher Investments on Technology" can help you quickly become familiar with this highly diversified sector, how the sector is segmented by industries, their respective macroeconomic drivers, and the challenges facing Technology firms.

This reliable guide skillfully addresses how to determine optimal times to invest in Technology stocks, and which industries and sub-industries have the potential to perform well in various environments. The global Technology sector is complex, including a variety of sub-industries and countries--each with their own unique characteristics. Using the framework found here, you'll discover how to identify these differences, spot opportunities, and avoid major pitfalls.

"Fisher Investments on Technology: " Discusses industry fundamentals, drivers, attributes, and potential challenges Addresses the challenges unique to Technology and some common pitfalls to avoid. Delves into top-down investment methodology as well as individual security analysis. Outlines a five-step process to help differentiate Technology firms--designed to help you identify ones that may have greatest probability of outperforming Provides investment strategies for a variety of market environments

Filled with in-depth insights and expert advice, "Fisher Investments on Technology" provides a framework for understanding this sector and its industries to help you make better investment decisions--now and in the future. With this book as your guide, you can gain a global perspective of the Technology sector and discover strategies to help achieve your investing goals.

Governments around the world have policies to promote links between industry and academic and government laboratories in order to foster economic growth and innovation in the technology-based industries. Knowledge Frontiers gives new insights into this process and offers an original framework for tracking these interactions. The book shows what 'knowledge' companies want from public sector research, and how they network to get this knowledge in three new and promising fields of advanced technology - biotechnology, engineering ceramics, and parallel computing. The authors first look at some of the background issues - policy issues about links between industry and public sector research; the ways in which science and technology interact in the innovation process; and general developments in each of the technologies examined. They look in more detail at public-private research links in the three areas. They find similarities which point to the general importance to innovation of frontier research in universities, and the need to encourage informal interaction/contact between industrial and public sector researchers. They also find differences between the fields which suggest that the policies to provide research links should be more effectively targeted, as an integral part of the broader objective of fostering 'strategic technologies'. Knowledge Frontiers advances our understanding of the various types of knowledge used in the course of research, design, and development leading to innovation. It is essential reading for those wanting to get to grips with the complex and dynamic realities of the innovation process - be they researchers, managers, or policy makers.

In the fall of 1980, Genentech, Inc., a little-known California genetic engineering company, became the overnight darling of Wall Street, raising over $38 million in its initial public stock offering. Lacking marketed products or substantial profit, the firm nonetheless saw its share price escalate from $35 to $89 in the first few minutes of trading, at that point the largest gain in stock market history. Coming at a time of economic recession and declining technological competitiveness in the United States, the event provoked banner headlines and ignited a period of speculative frenzy over biotechnology as a revolutionary means for creating new and better kinds of pharmaceuticals, untold profit, and a possible solution to national economic malaise. Drawing from an unparalleled collection of interviews with early biotech players, Sally Smith Hughes offers the first book-length history of this pioneering company, depicting Genentech's improbable creation, precarious youth, and ascent to immense prosperity. Hughes provides intimate portraits of the people significant to Genentech's science and business, including cofounders Herbert Boyer and Robert Swanson, and in doing so sheds new light on how personality affects the growth of science. By placing Genentech's founders, followers, opponents, victims, and beneficiaries in context, Hughes also demonstrates how science interacts with commercial and legal interests and university research, and with government regulation, venture capital, and commercial profits. Integrating the scientific, the corporate, the contextual, and the personal, "Genentech" tells the story of biotechnology as it is not often told, as a risky and improbable entrepreneurial venture that had to overcome a number of powerful forces working against it.

A TIMES BEST CURRENT AFFAIRS BOOK OF THE YEAR The award-winning Financial Times columnist exposes the threat that Big Tech poses to our democracies, our economies and ourselves 'Powerful' Sunday Times Google and Facebook receive 90% of the world's news advertising spend. Amazon takes half of all e-commerce in the US. Google and Apple operating systems run on all but 1% of cell phones globally. And 80% of corporate wealth is now held by 10% of companies - the digital titans. How did these once-idealistic and innovative companies come to manipulate elections, violate our privacy and pose a threat to the fabric of our democracy? Through her skilled reporting and unparalleled access, Rana Foroohar reveals the true extent to which the 'FAANG's (Facebook, Apple, Amazon, Netflix and Google) crush or absorb competitors, hijack our personal data and mental space and offshore their exorbitant profits. What's more, she shows how these threats to our democracies, livelihoods and minds are all intertwined. Yet Foroohar also lays out a plan for how we can resist, creating a framework that fosters innovation while protecting us from the dark side of digital technology. 'A masterful critique' Observer 'Insightful and powerfully argued' Daily Mail 'Essential reading ... whip-smart' Niall Ferguson 'Laser vision and trenchant business analysis' Shoshana Zuboff

PRAISE FOR Trading in the Zone

"Ari Kiev takes us inside the most successful trading firms of our time and shows us how those firms seek to improve performance through disciplined self analysis and structured goal management. His application of psychiatric tools to the short-term trading aspects of behavioral finance can give readers a competitive edge."–Charles A. Leeds Jr., CFA, Managing Member, Hermit Capital Management, LLC

"Kiev uses the powerful combination of his professional training as well as a unique vantage point inside the ropes at a market-moving, high-rolling hedge fund to deliver a fascinating analysis of a trader’s psyche. Although trading is widely acknowledged as an art, one that requires incredible innate intuition and feel for the markets, Kiev prescribes ‘getting into the zone’– a psychological state that one can create – for those aiming to achieve a higher level of performance. His anecdotes, case studies, interviews and tales of the ‘Master Trader’ are both instructive and tremendously insightful. A compelling read."–Ciaran T. O'Kelly, Head of Equity Trading, Salomon Smith Barney

"Trading in the Zone discusses the psychological considerations that serve to distinguish the most successful traders and portfolio managers from the majority of traders who are doomed to failure. Trading is so greatly influenced by emotions and discipline that not to have Ari’s insight and advice is a serious mistake."–Tom DeMark, author of The New Science of Technical Analysis

"I have been managing money for more than twenty years and I am happy to endorse Dr. Kiev’s principles, which have enhanced my performance and that of my traders over the past three years. Trading in the Zone will propel readers to the next level of trading success."–Jay Goldman, Hedge Fund Manager, J. Goldman & Co., L.P.

"Ari Kiev’s Trading in the Zone clearly and forcefully illustrates the mental discipline that will enable a stock trader to improve his performance."–Allan R. Tessler, Chairman and CEO, Jnet Enterprises

"Dr. Kiev works with professional traders, including some of the best traders in the country. In Trading in the Zone, he provides numerous case studies based on the market experiences of these traders, told both through narratives and their own words, in order to distill insights and lessons that should prove invaluable to professional and aspiring traders alike."–Jack Schwager, author of The Market Wizards and Stock Market Wizards

Flexible Electronics for Security, Manufacturing, and Growth in the United States is the summary of a workshop convened in September 2010 by Policy and Global Affairs' Board on Science, Technology, and Economic Policy to review challenges, plans, and opportunities for growing a robust flexible electronics industry in the United States. Business leaders, academic experts, and senior government officials met to review the role of research consortia around the world to advance flexible electronics technology. Presenters and participants sought to understand their structure, focus, funding, and likely impact, and to determine what appropriate steps the United States might consider to develop a robust flexible electronics industry. Flexible electronics refers to technologies that enable flexibility in the manufacturing process as well as flexibility as a characteristic of the final product. Features such as unconventional forms and ease of manufacturability provide important advantages for flexible electronics over conventional electronics built on rigid substrates. Today, examples of flexible electronics technologies are found in flexible flat-panel displays, medical image sensors, photovoltaic sheets, and electronic paper. Some industry experts predict that the market for global flexible electronics will experience a double digit growth rate, reaching $250 billion by 2025, but most experts believe that the United States is not currently poised to capitalize on this opportunity. Flexible Electronics for Security, Manufacturing, and Growth in the United States examines and compares selected innovation programs, both foreign and domestic, and their potential to advance the production of flexible electronics technology. Table of Contents Front Matter I OVERVIEW Overview II PROCEEDINGS Welcome Introduction Panel I: The Flexible Electronics Opportunity and Industry Challenges: Perspectives from Industry Panel II: The U.S. Interest: Security, Manufacturing, and Growth Panel III: What Is the Rest of the World Doing? Panel IV: What Is Needed? Opportunities for Collaborative Activity Panel V: Roundtable - Key Issues and Steps Forward III APPENDIXES Appendix A: Agenda Appendix B: Participants List Appendix C: Bibliography

The biohealthcare executive in upper-middle management confronts leadership challenges unique to their industry: they manage highly specialized knowledge workers and innovators, compete at the speed of technology, work in a highly regulated environment where "free speech" often does not apply due to patient safety and privacy concerns, and increasingly are leading virtual teams who may be located in different parts of the world. Practical leadership for biopharmaceutical executives is a guide that strips away the theory and meets head-on the practical leadership challenges these executives face on a daily basis, and provides these "innovator leaders" with the tools to lead effectively in the face of technological complexity.

This book analyses how China s firms in the consumer electronics (CE) sector have developed their business strategy and corporate governance during the reform process. The CE sector is one of China s most important and dynamic manufacturing sectors. As one of the earliest market-oriented sectors after 1978, its experience illustrates the adoption of the Western model of management in China. This is the first book to analyse the link between business strategy, corporate governance and performance of firms, explicitly comparing state-, collective-, and privately-owned firms. This book argues that the competitive dynamics of the market are central to the survival of firms in contemporary China.
Focuses on the state, collective and private Chinese firms in the consumer electronics sectorProvides insights into the interactions among political, economic and corporate factors in the China business environment that influence the strategies and performance of these firmsCompares the corporate governance of these Chinese firms across different ownership forms"